Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Annexon Biosciences (ANNX) and UnitedHealth (UNH)

Tipranks - Tipranks - Fri Apr 17, 4:54AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Danaher (DHR), Annexon Biosciences (ANNX) and UnitedHealth (UNH).

Claim 30% Off TipRanks

Danaher (DHR)

Bank of America Securities analyst Michael Ryskin maintained a Buy rating on Danaher yesterday and set a price target of $270.00. The company’s shares closed last Wednesday at $198.14, close to its 52-week low of $196.80.

According to TipRanks.com, Ryskin is a 3-star analyst with an average return of 1.4% and a 49.1% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $259.00, representing a 30.1% upside. In a report issued on April 6, Evercore ISI also assigned a Buy rating to the stock with a $225.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Annexon Biosciences (ANNX)

Needham analyst Joseph Stringer maintained a Buy rating on Annexon Biosciences today and set a price target of $11.00. The company’s shares closed last Wednesday at $6.35.

According to TipRanks.com, Stringer is a 5-star analyst with an average return of 24.8% and a 47.8% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Apellis Pharmaceuticals, and Vertex Pharmaceuticals. ;'>

Annexon Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $15.40, representing a 159.7% upside. In a report issued on April 1, Wells Fargo also reiterated a Buy rating on the stock with a $27.00 price target.

UnitedHealth (UNH)

TD Cowen analyst Ryan Langston assigned a Hold rating to UnitedHealth today and set a price target of $311.00. The company’s shares closed last Wednesday at $314.05.

According to TipRanks.com, Langston ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.1% and a 36.7% success rate. Langston covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Privia Health Group, and P3 Health Partners. ;'>

Currently, the analyst consensus on UnitedHealth is a Strong Buy with an average price target of $366.24, which is a 15.9% upside from current levels. In a report issued on April 7, Bank of America Securities also maintained a Hold rating on the stock with a $337.00 price target.

Read More on DHR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).